It seems like investors were hoping not only for positive data in HER2 + tumors but also HER2 negative rumors. The diarrhea is manageable with high dose Imodium (rate decreased to 5% with this strategy). And even without HER negative rumors neratinib could be a billion dollar drug. It looks better in terms of efficacy than herceptin and that's a $5b drug. Not saying it will displace it but if it gets most of the second and third line then there is still a big enough market to more than justify the current valuation. And if neratinib gets a role in neoadjuvant that it could be a multiple of $1b
Well, if what your saying it true then those investor are just ignorant of the facts. Neratinib was designed to bind to the kinase domain of the Her2 receptor. If the cancer lacks this receptor, then certainly it will not be effective against such cancers. I would have thought that this would be obvious.
Exactly. I feel the same way. I think there was some hope that it would be effective via other mechanisms on other types of breast cancer. I'm looking 12-18 months out but at $2b in market cap and the timeline for phase III and filing NDA still intact, I think we are at a reasonable valuation. There should be data within the next 3-6 months that should turn things around.